J. Cheng

发表

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Greil, K. Harrington, A. Psyrri, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Fas (CD95)‐transduced signal preferentially stimulates lupus peripheral T lymphocytes

N. Talal, A. Escalante, J. Cheng, 1998, European journal of immunology.

Traditional Chinese patent medicine for prophylactic treatment of migraine: a meta‐analysis of randomized, double‐blind, placebo‐controlled trials

L. Yuan, J. Cheng, Y. Xiao, 2015, European journal of neurology.

Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial.

J. Machiels, K. Harrington, M. Ahn, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.